See more : Mountain & Co. I Acquisition Corp. (MCAAW) Income Statement Analysis – Financial Results
Complete financial analysis of Savior Lifetec Corporation (4167.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Savior Lifetec Corporation, a leading company in the Biotechnology industry within the Healthcare sector.
- Ayr Wellness Inc. (AYR-A.CN) Income Statement Analysis – Financial Results
- IGM Financial Inc. (IGIFF) Income Statement Analysis – Financial Results
- Mashreqbank PSC (MASQ.AE) Income Statement Analysis – Financial Results
- Ryoyo Electro Corporation (8068.T) Income Statement Analysis – Financial Results
- The Edinburgh Investment Trust plc (EDIN.L) Income Statement Analysis – Financial Results
Savior Lifetec Corporation (4167.TWO)
About Savior Lifetec Corporation
Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent for intravenous infusion; and meropenem, a beta-lactamase resistant carbapenem antibiotic for parenteral administration. It also provides ertapenem, a form of carbapenem for use on gram-negative and gram-positive anaerobes and aerobic. The company's pipeline products include SLC-006 for prostate cancer endometriosis uterine leiomyoma; and sterile paliperidone palmitate API for the treatment of schizophrenia. Savior Lifetec Corporation was founded in 2004 and is headquartered in Miaoli County, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.05B | 1.27B | 1.74B | 1.83B | 1.32B | 1.10B | 1.62B | 1.53B | 1.12B | 1.02B | 1.00B | 837.82M | 786.34M |
| Cost of Revenue | 829.33M | 1.13B | 1.44B | 1.27B | 967.70M | 1.18B | 1.18B | 1.35B | 1.20B | 1.00B | 928.48M | 1.09B | 924.59M |
| Gross Profit | 220.95M | 130.99M | 307.87M | 558.64M | 350.99M | -70.49M | 440.34M | 186.90M | -82.40M | 18.58M | 72.16M | -247.76M | -138.26M |
| Gross Profit Ratio | 21.04% | 10.35% | 17.66% | 30.57% | 26.62% | -6.38% | 27.21% | 12.20% | -7.35% | 1.82% | 7.21% | -29.57% | -17.58% |
| Research & Development | 110.96M | 119.12M | 167.27M | 179.13M | 187.69M | 142.84M | 215.80M | 242.67M | 255.69M | 256.89M | 208.32M | 108.33M | 93.64M |
| General & Administrative | 76.05M | 76.32M | 79.66M | 97.47M | 72.85M | 73.49M | 68.34M | 65.46M | 73.97M | 63.58M | 43.00M | 42.88M | 40.20M |
| Selling & Marketing | 38.30M | 29.80M | 34.74M | 39.60M | 27.91M | 71.01M | 51.66M | 61.82M | 51.27M | 36.51M | 43.54M | 45.80M | 25.37M |
| SG&A | 112.41M | 106.12M | 114.40M | 137.07M | 100.76M | 144.50M | 120.00M | 127.28M | 125.24M | 100.09M | 86.54M | 88.68M | 65.57M |
| Other Expenses | 0.00 | 130.16M | -2.02M | 42.30M | -28.36M | 7.55M | -56.82M | 11.28M | -499.00K | -4.57M | 151.00K | 9.03M | 75.67M |
| Operating Expenses | 223.37M | 225.25M | 281.67M | 316.20M | 288.45M | 287.34M | 334.35M | 369.95M | 380.93M | 351.36M | 294.86M | 197.00M | 159.21M |
| Cost & Expenses | 1.05B | 1.36B | 1.72B | 1.58B | 1.26B | 1.46B | 1.51B | 1.72B | 1.58B | 1.35B | 1.22B | 1.28B | 1.08B |
| Interest Income | 44.25M | 16.10M | 494.00K | 2.31M | 2.17M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 238.00K | 507.00K |
| Interest Expense | 9.87M | 15.69M | 17.86M | 24.22M | 31.95M | 17.54M | 26.90M | 35.92M | 29.96M | 18.44M | 6.15M | 21.81M | 13.46M |
| Depreciation & Amortization | 182.16M | 208.72M | 238.65M | 221.60M | 213.32M | 206.52M | 202.78M | 207.33M | 203.36M | 165.75M | 128.71M | 119.48M | 106.16M |
| EBITDA | 219.61M | 260.73M | 263.33M | 508.65M | 247.50M | -135.49M | 251.95M | 35.55M | -260.47M | -171.60M | -96.39M | -301.84M | -114.94M |
| EBITDA Ratio | 20.91% | 20.60% | 15.10% | 27.84% | 18.77% | -13.01% | 15.57% | 2.32% | -23.24% | -16.84% | -9.38% | -36.27% | -14.43% |
| Operating Income | -2.42M | 52.00M | 24.68M | 287.05M | 34.18M | -357.83M | 105.99M | -183.05M | -463.33M | -332.78M | -222.70M | -444.76M | -297.47M |
| Operating Income Ratio | -0.23% | 4.11% | 1.42% | 15.71% | 2.59% | -32.39% | 6.55% | -11.95% | -41.35% | -32.66% | -22.26% | -53.09% | -37.83% |
| Total Other Income/Expenses | 29.96M | 130.57M | -16.24M | -36.11M | -67.47M | -9.99M | -83.72M | -24.64M | -30.46M | -23.01M | -6.00M | -8.07M | 62.91M |
| Income Before Tax | 27.54M | 36.31M | 9.96M | 250.94M | -4.93M | -359.55M | 22.27M | -207.70M | -493.79M | -355.79M | -228.70M | -452.83M | -234.56M |
| Income Before Tax Ratio | 2.62% | 2.87% | 0.57% | 13.73% | -0.37% | -32.55% | 1.38% | -13.56% | -44.06% | -34.92% | -22.86% | -54.05% | -29.83% |
| Income Tax Expense | 42.00K | 15.69M | 14.72M | 36.11M | 39.11M | 15.82M | -56.82M | 11.28M | -499.00K | -4.57M | 151.00K | 21.41M | 77.84M |
| Net Income | 30.03M | 20.62M | -4.76M | 250.94M | -44.05M | -359.55M | 22.27M | -207.70M | -493.79M | -355.79M | -228.70M | -452.83M | -234.56M |
| Net Income Ratio | 2.86% | 1.63% | -0.27% | 13.73% | -3.34% | -32.55% | 1.38% | -13.56% | -44.06% | -34.92% | -22.86% | -54.05% | -29.83% |
| EPS | 0.09 | 0.07 | -0.02 | 0.84 | -0.16 | -1.40 | 0.09 | -0.85 | -2.49 | -2.01 | -1.40 | -3.18 | -1.76 |
| EPS Diluted | 0.09 | 0.07 | -0.02 | 0.76 | -0.16 | -1.38 | 0.09 | -0.84 | -2.48 | -1.98 | -1.37 | -3.10 | -1.76 |
| Weighted Avg Shares Out | 317.30M | 317.02M | 316.74M | 298.99M | 271.25M | 256.01M | 259.67M | 245.80M | 198.30M | 177.08M | 162.85M | 142.24M | 133.17M |
| Weighted Avg Shares Out (Dil) | 338.60M | 317.08M | 317.54M | 336.69M | 271.25M | 260.25M | 260.07M | 247.48M | 199.02M | 179.84M | 167.16M | 146.00M | 133.17M |
Source: https://incomestatements.info
Category: Stock Reports